A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

Influenza, Human Clinical Trial

Official title:

A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02914275
• Other study ID #: CSLCT-QIV-15-03
• Status: Completed
• Phase: Phase 3
• Start date: September 27, 2016
• Est. completion date: August 11, 2017

Study information

• Verified date: November 2018
• Source: Seqirus
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 6 months through 59 months of age.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2250
• Est. completion date: August 11, 2017
• Est. primary completion date: March 9, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Months to 59 Months

Eligibility

Inclusion Criteria:

• Male or female subject 6 months through to 59 months of age at the time of first vaccination and born between 36 and 42 weeks of gestation;

• Parent or legally acceptable representative able to provide written informed consent and be willing and able to adhere to all protocol requirements including blood draws.

• Subject is in generally good health as per the Investigator's medical judgment

Exclusion Criteria:

• History of allergic reactions to egg proteins or any components of the Study Vaccines;

• History of serious adverse reactions to any influenza vaccines;

• History of Guillain-Barré syndrome or other demyelinating disease such as encephalomyelitis and transverse myelitis;

• History of licensed or investigational influenza vaccination in the last 6 months;

• Clinical signs of active infection and/or an axillary temperature of = 99.5°F / (= 37.5 °C) on the day of vaccination or within 48 hours preceding vaccination.

• Current or recent, acute or chronic medical conditions that in the opinion of the Investigator are clinically significant and/or unstable

• History of any seizures, with the exception of a single febrile seizure;

• Self-reported or known seropositivity suggestive of acute or chronic viral infection for human immunodeficiency virus, hepatitis B or hepatitis C;

• Known or suspected congenital or acquired immunosuppressive conditions;

• Current or recent immunosuppressive or immunomodulatory therapy

• Current or medical history of malignant neoplasms;

• Administration of immunoglobulin and/or any blood products within the previous 90 days preceding the administration of the Study Vaccine or planned administration during the study;

• Participation in a clinical trial or use of an investigational compound within 28 days prior to or 28 days after receiving the Study Vaccine, or plans to enter a study during this period;

• Vaccination with a licensed vaccine 21 days (for live or inactivated vaccines) prior to receiving the Study Vaccine, or plans to receive any licensed vaccine prior to the Study Exit Visit.

• Medical conditions or treatment contraindicating intramuscular vaccination due to increased risk of bleeding.

• Family members of the employees of the Investigator or study center with direct involvement in the study, or with other clinical studies under the direction of that Investigator or study center.

Related Conditions & MeSH terms

• Influenza, Human

Intervention

Biological:
• Seqirus Quadrivalent Inactivated Influenza Vaccine
The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season). Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age.
• Comparator Quadrivalent Inactivated Influenza Vaccine
The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season. Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection of the non-dominant arm in children 36 months through 59 months of age.

Locations

Country	Name	City	State
United States	Site 430	Anaheim	California
United States	Site 437	Anaheim	California
United States	Site 429	Asheboro	North Carolina
United States	Site 390	Augusta	Kansas
United States	Site 283	Austin	Texas
United States	Site 285	Binghamton	New York
United States	Site 434	Birmingham	Alabama
United States	Site 308	Bristol	Tennessee
United States	Site 419	Charleston	South Carolina
United States	Site 438	Charlottesville	Virginia
United States	Site 446	Cincinnati	Ohio
United States	Site 427	Dayton	Ohio
United States	Site 423	Downey	California
United States	Site 282	Fort Worth	Texas
United States	Site 444	Kingsport	Tennessee
United States	Site 395	Layton	Utah
United States	Site 420	Louisville	Kentucky
United States	Site 441	Louisville	Kentucky
United States	Site 443	Louisville	Kentucky
United States	Site 289	Meridian	Idaho
United States	Site 393	Metairie	Louisiana
United States	Site 436	Metairie	Louisiana
United States	Site 418	Miami	Florida
United States	Site 426	Miami	Florida
United States	Site 442	Mobile	Alabama
United States	Site 421	Newton	Kansas
United States	Site 397	Ontario	California
United States	Site 445	Paramount	California
United States	Site 402	Sacramento	California
United States	Site 424	Salt Lake City	Utah
United States	Site 428	Salt Lake City	Utah
United States	Site 431	Salt Lake City	Utah
United States	Site 288	San Angelo	Texas
United States	Site 425	San Diego	California
United States	Site 439	Spartanburg	South Carolina
United States	Site 433	West Jordan	Utah
United States	Site 435	West Jordan	Utah
United States	Site 440	West Jordan	Utah
United States	Site 422	Wichita	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Seqirus

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Geometric Mean Titer (GMT) Ratio of Each Virus Strain.	Noninferiority of Seqirus QIV compared to comparator QIV was assessed by hemagglutination inhibition (HI) antibody geometric mean titer (GMT) for each viral strain included in the vaccines. The GMT ratio is defined as the geometric mean of the postvaccination HI titer for the US-licensed comparator QIV over the geometric mean of the postvaccination HI titer for Seqirus QIV.; B/VIC = B/Victoria B/YAM = B/Yamagata	Postvaccination (28 days after last vaccination)
Primary	The Difference in Seroconversion Rate (SCR) for Each Virus Strain.	Noninferiority of Seqirus QIV compared to comparator QIV will be assessed by seroconversion rate (SCR) for each viral strain. SCR is defined as the percentage of subjects with either a prevaccination HI titer < 1:10 and a postvaccination HI titer = 1:40, or a prevaccination HI titer = 1:10 and a = 4-fold increase in postvaccination HI titer. For the SCR comparison, the difference between the SCR for each vaccine (for each strain) will be determined.	Postvaccination (28 days after last vaccination)
Secondary	Number of Participants With Solicited Local Adverse Reactions and Solicited Systemic Adverse Events (AE)	Frequency and severity of solicited local adverse reactions and systemic AEs for 7 days after each vaccination dose	Postvaccination (up to 7 days after vaccination)
Secondary	Number of Participants With Cellulitis-like Reactions	Frequency of cellulitis-like reactions for at least 28 days after each vaccination dose	Postvaccination (up to 28 days after each vaccination)
Secondary	Number of Participants With Unsolicited AEs	Frequency and severity of unsolicited AEs for at least 28 days after each vaccination dose	Postvaccination (up to 28 days after vaccination)
Secondary	Number of Participants With Serious Adverse Events (SAE)	Frequency of SAEs for 180 days after the last vaccination dose. SAE = serious adverse events, AESI = adverse event of special interest	180 days after the last vaccination dose.
Secondary	Geometric Mean of Hemagglutination Titers (HI GMTs) Prevaccination (Day 1) and Postvaccination (Study Exit Visit) of Each Virus Strain	The humoral immune response will be assessed for Seqirus QIV & comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate geometric mean of HI titers prevaccination & postvaccination.	28 days after last vaccination.
Secondary	Seroconversion Rates (SCRs) of Each Virus Strain	The humoral immune response will be assessed for Seqirus QIV & comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate SCRs defined as the % of subjects with either a prevaccination HI titer < 1:10 and a postvaccination HI titer = 1:40 or a prevaccination titer = 1:10 and a = 4-fold increase in postvaccination titer.	28 days after last vaccination
Secondary	Seroprotection Rates of Each Virus Strain	The humoral immune response will be assessed for Seqirus QIV & comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate the percentage of subjects with a titer =40 (seroprotection rates) at Day 1 and at Study Exit Visit.	28 days after last vaccination.
Secondary	Geometric Mean Fold Increase (GMFI) of Each Virus Strain	The humoral immune response will be assessed for Seqirus QIV & comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate GMFIs, defined as the geometric mean fold titer change (rise) from Day 1 to Study Exit Visit.	Prevaccination (Day 1) and Postvaccination (28 days after last vaccination)